Mazen Noureddin, MD, is the Director of Fatty Liver Program at Cedars-Sinai Medical Center with a focus on translational research, particularly in nonalcoholic fatty liver disease (NAFLD). Dr. Noureddin has conducted investigational, translational and clinical studies of novel treatments for nonalcoholic steatohepatitis (NASH). One of the pathogenesis pathways that he is currently investigating is the role of S-adenosylmethionine (SAMe) in NAFLD/NASH.
Dr. Noureddin began working on hepatic SAMe during his internal medicine residency at the University of Southern California (USC) in the laboratory of Shelly Lu, MD. Following his residency, he moved to the National Institutes of Health (NIH), where he was enrolled in a three-year Hepatology Fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, which included a combined NIH/Duke University Master of Health Sciences in Clinical Research certification.
After his NIH fellowship, Dr. Noureddin embarked on a two-year gastroenterology fellowship at the University of California, San Diego, where he focused on NAFLD and NASH and assessing the clinical utility of a new liver-imaging technique, MRI-proton density fat fraction (MRI-PDF). This scanning methodology is currently considered the new reference standard for the imaging of the fatty liver in NAFLD patients.